23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Corporate solution
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Welcome to our Corporate client solution

    Here you can administrate your corporate solutions users.

  • Welcome to your subscription for Life Science Focus

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Focus.

  • Click here to go to sign-up
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Try Life Science Focus now
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Decision on rival CAR-T therapies: Yes to Yescarta, no to Breyanzi

Sweden’s Council for New Therapies (NT-rådet) has assessed two CAR-T therapies for follicular lymphoma, reaching very different conclusions.
Advertisement

Follicular lymphoma is a type of non-Hodgkin lymphoma, a cancer that develops in the lymphatic system. According to the Swedish Cancer Society, around 250 people in Sweden are diagnosed with the disease each year, and its prognosis varies considerably.

There are currently two CAR-T therapies approved in the EU for the treatment of follicular lymphoma: Yescarta, from Gilead Sciences, and Breyanzi, from Bristol Myers Squibb.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.109|instance-web02